Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA urged to act on cough/cold medicines

This article was originally published in The Tan Sheet

Executive Summary

Sen. Chris Dodd, D-Conn., has urged FDA Commissioner Andrew von Eschenbach to provide an update on FDA's plan for acting on the recommendations of its advisory committees regarding a "no use" suggestion for cough and cold medicines for children under the age of 6 due to safety concerns. In a letter dated Nov. 1, Dodd asks FDA to take "aggressive action" on the issue, suggesting "at a minimum, these products should be immediately relabeled to reflect the recommendations" of the advisory committees. A senior Democrat on the Senate Committee on Health, Education, Labor and Pensions and the chairman of its Subcommittee on Children and Families, Dodd notes he is "troubled" that agency officials have been quoted in press reports as "merely urging parents to continue following directions on these products" when the panels found the labels to be misleading. He also expresses concern FDA will act slowly on the issue, citing its regulatory approach on issuing a final monograph for sunscreen UVA/UVB protection...

You may also be interested in...

Health And Wellness Trademark Review 14 January, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention

Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.

Deal Watch: Novo Nordisk, Fauna To Explore Hibernation To Treat Obesity

A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts